Biosimilar Committee Roster Shows More Focus On Analytics For Inflectra
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA adds experts in protein engineering and physicochemical characterization to second biosimilar advisory committee after concerns there was too much clinical discussion at first meeting.